RESUMEN
Context: Breast abscess is the most common complication of acute bacterial mastitis usually referred to as pyogenic mastitis. It is usually encountered during lactation due to an infection with Staphylococcus aureus and streptococcal bacteria. These bacteria produce a severe inflammatory reaction leading to pus formation which is mainly treated by ultrasound-guided drainage or fine needle aspirations. We find that in this condition homoeopathic treatment can play an important role as it avoids such surgical procedures and helps in healing in a most gentle and rapid way. We report a successful single case study that opens up opportunities to take up more such cases to strengthen the results of this report. Case summary: A 23-year-old lactating mother came with complaints of pain and swelling with a collection of pus in the breast region and decreased breast milk secretion. Individualised homoeopathic medicine Silicea 200C was given to hasten suppuration and Belladonna 200C to treat inflammation.Thus, this case shows us how only few doses of medicine may be quickly helpful in managing a case of breast abscess without the need of any surgical procedures.
Asunto(s)
Enfermedades de la Mama , Homeopatía , Mastitis , Femenino , Humanos , Adulto Joven , Adulto , Enfermedades de la Mama/terapia , Enfermedades de la Mama/complicaciones , Absceso/etiología , Absceso/microbiología , Lactancia , Homeopatía/efectos adversos , Mastitis/etiología , Mastitis/microbiología , Supuración/complicacionesRESUMEN
National guidelines for treatment of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hyponatremia have been approved by the Danish Society of Gastroenterology and Hepatology. Ascites develops in approximately 60% of patients with cirrhosis during a 10 year period and is frequently associated with complications that determine the course of the disease and the prognosis. These evidence-based guidelines are divided in two parts and consider definitions, pathophysiology, diagnostic aspects, treatment, and prophylaxis.
Asunto(s)
Antibacterianos/uso terapéutico , Ascitis , Diuréticos/uso terapéutico , Cirrosis Hepática/complicaciones , Paracentesis/métodos , Peritonitis , Ascitis/diagnóstico , Ascitis/etiología , Ascitis/metabolismo , Ascitis/fisiopatología , Ascitis/terapia , Líquido Ascítico/metabolismo , Líquido Ascítico/microbiología , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/fisiopatología , Infecciones Bacterianas/terapia , Protocolos Clínicos/normas , Terapia Combinada , Medicina Basada en la Evidencia/normas , Humanos , Cirrosis Hepática/fisiopatología , Pruebas de Sensibilidad Microbiana , Peritonitis/diagnóstico , Peritonitis/microbiología , Peritonitis/fisiopatología , Peritonitis/terapia , Supuración/complicaciones , Supuración/fisiopatologíaRESUMEN
BACKGROUND: Inflammatory dermatoses in conjunction with inflammatory bowel disease (IBD) comprise a diverse range of disorders. Some but not all of these respond to conventional treatments for the underlying IBD, such as immunomodulating or antibiotic treatments. We describe our experience with high dose vitamin B12, where conventional therapies have failed. CASE REPORTS: The first case had pouchitis complicated by perianal abscesses and a recto-vaginal fistula. The second case had biopsy proven hidradenitis suppurativa affecting the perianal, inguinal and pubic skin. High dose vitamin B12 appeared to be the major factor in preventing the recurrence of suppuration in both patients. Neither patient had vitamin B12 deficiency. Open label experience: high dose vitamin B12 treatment of a further 10 consecutive IBD patients with dermatoses was thought to provide benefit to six of them, but did not appear useful in four patients with perianal Crohn's disease with fistulae as the only manifestation of cutaneous disease. CONCLUSIONS: There appears to be a subset of IBD patients with perianal and more distant inflammatory dermatoses, who benefit from high dose vitamin B12 treatment. Clinical trials in IBD patients with biopsy-characterised suppurative dermatoses will be required in order to properly define the role of this safe and economical therapy.